Author

A. Chase

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Approach:experimental assay· 1 Assay:Hi-C· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Approach:statistical model· 1 Research Focus:transcription & RNA processing· 1

Frequent Co-Authors

A. L. Cathcart· 1 shared A. Park· 1 shared A. Sahakyan· 1 shared A. Sarusi Portugez· 1 shared A. Telenti· 1 shared A. Werts· 1 shared B. Guarino· 1 shared B. Sloan· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. L. Cathcart

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2

A. L. Cathcart, C. Havenar-Daughton, F. A. Lempp, D. Ma, M. Schmid, M. L. Agostini, B. Guarino, J. Di iulio, L. Rosen, H. Tucker, J. Dillen, S. Subramanian, B. Sloan, S. Bianchi, J. Wojcechowskyj, , C. M. Hebner

This paper evaluates the in vitro and in vivo efficacy of dual-action monoclonal antibodies VIR-7831 and VIR-7832 against SARS-CoV-2, showing potent neutralization and reduced viral load in a hamster model.

bioRxiv · Mar 9, 2021 · PreprintImmunology

Genomic Retargeting of Tumor Suppressors p53 and CTCF Promotes Oncogenesis

M. Schwartz, A. Sarusi Portugez, B. Zukerman Attia, M. Tannenbaum, O. Loza, A. Chase, Y. Turman, T. Kaplan, Z. Salah, O. Hakim

The paper identifies p53 and CTCF as key regulators of transcriptional reprogramming in early oncogenic transformation driven by HRas, showing that chromatin redistribution, not expression changes, drives malignancy.

bioRxiv · Jul 23, 2019 · PreprintCell Biology